Opinion

Video

A Review of the Data for Fusion-Based Biopsy Procedures

Author(s):

David I. Lee, MD, FACS,Firas F. Abdollah, MD

The panel discusses data on the accuracy of MRI-targeted or fusion-based biopsy procedures compared with systemic biopsy or MRI alone.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      Related Videos
      Jim Hu, MD, on upgrading of GG1 prostate cancer at radical prostatectomy
      Jim Hu, MD, on upgrading of GG1 prostate cancer at radical prostatectomy
      Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
      Expert discusses differentiating prostate cancer from age-related issues
      Howard Goldman, MD, discusses development of the Glean Urodynamics System
      Howard Goldman, MD, discusses development of the Glean Urodynamics System
      Murilo De Almeida Luz, MD, on PSA and ALP changes with enzalutamide/radium-223
      Murilo De Almeida Luz, MD, on PSA and ALP changes with enzalutamide/radium-223
      Ruben Olivares, MD, answers a question during a Zoom video interview
      Ruben Olivares, MD, discusses remote robot–assisted HIFU for prostate cancer
      Doctor consulting patient | Image Credit: © Liudmila Dutko - stock.adobe.com
      Strategies to bridge gender disparities in AAS and citations in the oncology literature
      Stacy Loeb, MD, MSc, PhD (Hon), answers a question during a Zoom video interview
      Stacy Loeb, MD, MSc, PhD (Hon), discusses the nuances of prostate cancer screening
      1 expert in this video
      Selecting Between Receptor Pathway Inhibitors for mHSPC
      1 expert in this video
      The Use of Ultra-Low PSA in Specific Patient Profiles
      Fred Saad, MD, FRCS, discusses clinical impact of darolutamide approval in mCSPC
      Fred Saad, MD, FRCS, discusses clinical impact of darolutamide approval in mCSPC
      Related Content
      Phase 3 trial launches of ifinatamab deruxtecan vs chemotherapy in mCRPC
      June 18th 2025

      Phase 3 trial launches of ifinatamab deruxtecan vs chemotherapy in mCRPC

      Hannah Clarke
      The IDeate-Prostate01 trial plans to enroll approximately 1440 patients whose tumors progressed following prior treatment with an ARPI.
      Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025 | Credit: Urology Times
      April 27th 2025

      Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

      Amy M. Pearlman, MD Helen L. Bernie, DO, MPH
      Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.
      FDA does not approve talazoparib plus enzalutamide for non-HRR gene mutated mCRPC
      June 17th 2025

      FDA does not approve talazoparib plus enzalutamide for non-HRR gene mutated mCRPC

      Hannah Clarke
      Pfizer has chosen to no longer pursue an expanded indication for talazoparib plus enzalutamide in non-HRR gene mutated mCRPC in the US as a result of this decision.
      Dr. Murphy on increasing diversity in cancer clinical trials
      February 29th 2024

      Dr. Murphy on increasing diversity in cancer clinical trials

      Urology Times staff
      In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
      Cleveland Clinic is First to Use Wireless, Catheter-Free Device to Monitor Bladder Dysfunction in Patients
      June 11th 2025

      Cleveland Clinic is First to Use Wireless, Catheter-Free Device to Monitor Bladder Dysfunction in Patients

      Cleveland Clinic
      Glean™ Urodynamics System developed by Bright Uro based on foundational technology created at Cleveland Clinic; Device received FDA clearance earlier this year
      Adding cetrelimab to niraparib maintenance shows benefit in aggressive variant prostate cancer
      June 11th 2025

      Adding cetrelimab to niraparib maintenance shows benefit in aggressive variant prostate cancer

      Hannah Clarke
      However, this regimen was associated with substantial toxicity, so careful patient selection is paramount, according to the authors.
      © 2025 MJH Life Sciences

      All rights reserved.